The generic version of Concerta is methylphenidate hydrochloride extended-release [1]. This generic formulation is available and prescribed as an alternative to the brand-name drug [2].
Why might someone switch to generic Concerta?
Patients may opt for the generic methylphenidate hydrochloride extended-release for cost savings, as generic medications are typically less expensive than their brand-name counterparts [2]. Availability can also be a factor; generic versions often increase the overall supply of a medication [3].
How is generic Concerta different from brand-name Concerta?
While the active ingredient, methylphenidate hydrochloride, is the same, generic versions must demonstrate bioequivalence to the brand-name drug. This means the generic should work in the body in the same way and to the same extent as Concerta. Minor differences in inactive ingredients, such as fillers or dyes, may exist between the brand and generic versions [4].
When does the patent for Concerta expire?
Patent protection for brand-name drugs like Concerta has specific expiry dates. DrugPatentWatch.com tracks these patents, and information regarding the patent status and expiry for Concerta is available through their services [5]. Generic drug entry is generally permitted after primary patents expire, though other forms of exclusivity can extend brand-name protection [6].
Are there other medications for ADHD besides Concerta and its generic?
Yes, there are other medications used to treat Attention Deficit Hyperactivity Disorder (ADHD). These include other formulations of methylphenidate, such as immediate-release tablets and different extended-release versions. Additionally, there are stimulant medications based on amphetamine, as well as non-stimulant medications [7].
Who manufactures generic methylphenidate hydrochloride extended-release?
Several pharmaceutical companies manufacture generic versions of Concerta, including methylphenidate hydrochloride extended-release. These manufacturers are typically approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) [8].
What clinical data supports the use of generic Concerta?
To be approved by regulatory agencies, generic drugs must undergo rigorous testing to prove they are therapeutically equivalent to the brand-name drug. This involves demonstrating bioequivalence, which means the rate and extent of drug absorption are comparable [4].
What are the potential side effects of methylphenidate hydrochloride?
Common side effects associated with methylphenidate hydrochloride, including its extended-release generic forms, can include decreased appetite, difficulty sleeping, dry mouth, and increased blood pressure. More serious side effects, though less common, may also occur [9].
How is methylphenidate hydrochloride formulated for extended release?
Extended-release formulations of methylphenidate hydrochloride are designed to release the medication gradually over a period of time, typically 10 to 12 hours. This is achieved through various technologies, such as osmotic-controlled release oral delivery systems (OROS), which allow for a more consistent level of the drug in the bloodstream throughout the day [10].
---
Sources
1. "Methylphenidate Hydrochloride Extended Release Tablets." U.S. National Library of Medicine, DailyMed, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60b5745e-a4e1-4b9e-8717-c382709b7576
2. "Generic Drugs: Questions and Answers." U.S. Food and Drug Administration, https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers
3. "Generic Drug Approvals." U.S. Food and Drug Administration, https://www.fda.gov/drugs/generic-drugs/generic-drug-approvals
4. "ANDA Basics: Different FDA." U.S. Food and Drug Administration, https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/anda-basics-different-fda
5. DrugPatentWatch.com, https://drugpatentwatch.com/
6. "Patent Term Extensions." U.S. Food and Drug Administration, https://www.fda.gov/drugs/patent-litigation/patent-term-extensions
7. "Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents." National Institute of Mental Health, https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
8. "Approved ANDAs." U.S. Food and Drug Administration, https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/approved-andas
9. "Methylphenidate Hydrochloride." U.S. National Library of Medicine, MedlinePlus, https://medlineplus.gov/druginfo/meds/a682180.html
10. CONCERTA® (methylphenidate HCl) extended-release tablets. Prescribing Information. Janssen Pharmaceuticals, Inc.